Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
Aims Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. Methods and results The interplay of RHR an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
4 October 2022
|
| In: |
European journal of heart failure
Year: 2022, Volume: 24, Issue: 10, Pages: 1883-1891 |
| ISSN: | 1879-0844 |
| DOI: | 10.1002/ejhf.2677 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ejhf.2677 Verlag, lizenzpflichtig, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2677 
|
| Author Notes: | Michael Böhm, Javed Butler, Felix Mahfoud, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Jonathan Slawik, Martina Brueckmann, Bruno Linetzky, Elke Schüler, Christoph Wanner, Faiez Zannad, Milton Packer, and Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1854008994 | ||
| 003 | DE-627 | ||
| 005 | 20240307085613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230801s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.2677 |2 doi | |
| 035 | |a (DE-627)1854008994 | ||
| 035 | |a (DE-599)KXP1854008994 | ||
| 035 | |a (OCoLC)1425217120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Böhm, Michael |d 1958- |e VerfasserIn |0 (DE-588)1096256169 |0 (DE-627)856690694 |0 (DE-576)467967482 |4 aut | |
| 245 | 1 | 0 | |a Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial |c Michael Böhm, Javed Butler, Felix Mahfoud, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Jonathan Slawik, Martina Brueckmann, Bruno Linetzky, Elke Schüler, Christoph Wanner, Faiez Zannad, Milton Packer, and Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
| 264 | 1 | |c 4 October 2022 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.08.2023 | ||
| 520 | |a Aims Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. Methods and results The interplay of RHR and empagliflozin effects in EMPEROR-Preserved was evaluated. We grouped patients (n = 5988) according to their baseline RHR (<70 bpm [n = 2650], 70-75 bpm [n = 967], >75 bpm [n = 1736]) and explored the influence of RHR on CVD or HHF (primary outcome) and its components in sinus rhythm or atrial fibrillation/flutter (AF) and adverse events. We studied the efficacy of empagliflozin across the RHR spectrum. Compared to placebo, empagliflozin did not change heart rate over time. The primary outcome (p for trend = 0.0004) and its components CVD (p trend = 0.0002), first HHF (p for trend = 0.0099) and all-cause death (p < 0.0001) increased with RHR only in sinus rhythm but not AF. The risk increase with RHR was similar in patients with heart failure and mildly reduced ejection fraction (left ventricular ejection fraction [LVEF] 40-49%) and HFpEF (LVEF ≥50%). Baseline RHR had no influence on the effect of empagliflozin on the primary outcomes (p for trend = 0.20), first HHF (p for trend = 0.49). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the RHR groups. Conclusion Resting heart rate associates with outcomes only in sinus rhythm but not in AF. Empagliflozin reduced outcomes over the entire RHR spectrum without increase of adverse events. | ||
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Cardiovascular outcomes | |
| 650 | 4 | |a Empagliflozin | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Resting heart rate | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahfoud, Felix |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pocock, Stuart J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Slawik, Jonathan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Linetzky, Bruno |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schüler, Elke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wanner, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d Oxford : Wiley, 1999 |g 24(2022), 10 vom: Okt., Seite 1883-1891 |h Online-Ressource |w (DE-627)306658291 |w (DE-600)1500332-2 |w (DE-576)081985983 |x 1879-0844 |7 nnas |a Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:10 |g month:10 |g pages:1883-1891 |g extent:9 |a Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ejhf.2677 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2677 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230801 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |e 60000PB121145069 |k 0/60000/ |p 8 | ||
| 999 | |a KXP-PPN1854008994 |e 4361711968 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 01.08.2023"],"title":[{"title":"Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial","title_sort":"Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial"}],"person":[{"role":"aut","given":"Michael","roleDisplay":"VerfasserIn","family":"Böhm","display":"Böhm, Michael"},{"family":"Butler","display":"Butler, Javed","roleDisplay":"VerfasserIn","given":"Javed","role":"aut"},{"role":"aut","given":"Felix","roleDisplay":"VerfasserIn","family":"Mahfoud","display":"Mahfoud, Felix"},{"role":"aut","given":"Gerasimos","roleDisplay":"VerfasserIn","display":"Filippatos, Gerasimos","family":"Filippatos"},{"display":"Ferreira, João Pedro","family":"Ferreira","roleDisplay":"VerfasserIn","given":"João Pedro","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Pocock, Stuart J.","family":"Pocock","given":"Stuart J.","role":"aut"},{"display":"Slawik, Jonathan","family":"Slawik","roleDisplay":"VerfasserIn","role":"aut","given":"Jonathan"},{"display":"Brückmann, Martina","family":"Brückmann","roleDisplay":"VerfasserIn","role":"aut","given":"Martina"},{"given":"Bruno","role":"aut","display":"Linetzky, Bruno","family":"Linetzky","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Schüler","display":"Schüler, Elke","given":"Elke","role":"aut"},{"role":"aut","given":"Christoph","roleDisplay":"VerfasserIn","display":"Wanner, Christoph","family":"Wanner"},{"given":"Faiez","role":"aut","family":"Zannad","display":"Zannad, Faiez","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Milton","roleDisplay":"VerfasserIn","display":"Packer, Milton","family":"Packer"},{"display":"Anker, Stefan D.","family":"Anker","roleDisplay":"VerfasserIn","role":"aut","given":"Stefan D."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"id":{"doi":["10.1002/ejhf.2677"],"eki":["1854008994"]},"physDesc":[{"extent":"9 S."}],"recId":"1854008994","name":{"displayForm":["Michael Böhm, Javed Butler, Felix Mahfoud, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Jonathan Slawik, Martina Brueckmann, Bruno Linetzky, Elke Schüler, Christoph Wanner, Faiez Zannad, Milton Packer, and Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators"]},"relHost":[{"origin":[{"publisherPlace":"Oxford ; Amsterdam [u.a.] ; Oxford [u.a.] ; Oxford","dateIssuedKey":"1999","publisher":"Oxford University Press ; Elsevier Science ; Oxford Univ. Press ; Wiley","dateIssuedDisp":"1999-"}],"disp":"Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialEuropean journal of heart failure","pubHistory":["1.1999 -"],"part":{"issue":"10","extent":"9","text":"24(2022), 10 vom: Okt., Seite 1883-1891","year":"2022","pages":"1883-1891","volume":"24"},"recId":"306658291","titleAlt":[{"title":"EJHF"}],"language":["eng"],"id":{"issn":["1879-0844"],"zdb":["1500332-2"],"eki":["306658291"],"doi":["10.1002/(ISSN)1879-0844"]},"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 07.01.25"],"title":[{"title":"European journal of heart failure","subtitle":"journal of the Working Group on Heart Failure of the European Society of Cardiology","title_sort":"European journal of heart failure"}]}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"4 October 2022"}]} | ||
| SRT | |a BOEHMMICHAHEARTFAILU4202 | ||